Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Atyr PHARMA in a report released on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.17) for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Atyr PHARMA's current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Atyr PHARMA's Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.55) EPS and FY2026 earnings at ($0.41) EPS.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02.
Other equities analysts have also issued reports about the stock. Leerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Friday, March 14th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Atyr PHARMA presently has a consensus rating of "Buy" and a consensus price target of $18.60.
Check Out Our Latest Stock Report on ATYR
Atyr PHARMA Stock Down 8.5%
ATYR stock traded down $0.28 during midday trading on Monday, hitting $3.03. The company's stock had a trading volume of 2,014,716 shares, compared to its average volume of 915,729. The company has a market cap of $269.68 million, a PE ratio of -3.22 and a beta of 0.79. The firm's 50-day moving average is $3.27 and its 200-day moving average is $3.40. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.
Institutional Trading of Atyr PHARMA
Institutional investors and hedge funds have recently made changes to their positions in the company. Group One Trading LLC purchased a new position in shares of Atyr PHARMA in the 4th quarter valued at $26,000. Alterna Wealth Management Inc. purchased a new position in shares of Atyr PHARMA in the 4th quarter valued at $36,000. Victory Capital Management Inc. purchased a new stake in shares of Atyr PHARMA during the fourth quarter valued at about $37,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Atyr PHARMA during the first quarter valued at about $38,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Atyr PHARMA during the fourth quarter valued at about $39,000. 61.72% of the stock is currently owned by institutional investors.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Articles
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
